BioCardia (BCDA) Net Cash Flow Growth (3y) (2015 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Net Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | -36.28% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 30.02% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -63.92% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 93.57% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 21.38% |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | 97.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 97.77% |
| Mar 31, 2026 | 14.89% |
| Dec 31, 2025 | -81.81% |
| Sep 30, 2025 | 61.50% |
| Jun 30, 2025 | 26.48% |
| Mar 31, 2025 | 21.52% |
| Dec 31, 2024 | 5.33% |
| Sep 30, 2024 | 49.21% |
| Jun 30, 2024 | 29.26% |
| Mar 31, 2024 | -53.56% |
| Dec 31, 2023 | -27.08% |
| Sep 30, 2023 | 12.56% |
| Jun 30, 2023 | 38.27% |
| Mar 31, 2023 | 5.80% |
| Dec 31, 2022 | 30.24% |
| Sep 30, 2022 | -9.28% |
| Jun 30, 2022 | 17.23% |
| Mar 31, 2022 | -5.30% |
| Dec 31, 2021 | -96.66% |
| Sep 30, 2021 | -9.65% |